Abstract
Gout is a form of arthritis caused by inflammatory crystals of monosodium urate, which deposit in joints when the plasma concentration of uric acid chronically exceeds the limit of solubility, ∼7 mg/dL (0.42 mM). The human species is predisposed to hyperuricemia and gout by mutation of the urate oxi dase gene during evolution. Urate oxidases from various sources have been used as a model to inves tigate the effects of PEGylation in animals. More than 15 years ago we initiated a project to develop a PEGylated recombinant mammalian urate oxidase as an Orphan Drug for treating patients with refractory gout. Clinical testing of this PEG-uricase, now called pegloticase, began in 2001. Pegloticase was found to have a half-life in plasma of about two weeks, and when infused at 2–4 week intervals to rapidly correct hyperuricemia. PEGylation was effective in limiting immune recognition of the recombinant uricase protein, but antibodies to PEG develop in some patients, resulting in the rapid clearance of pegloticase and loss of efficacy. However, in many patients with refractory gout, treatment with pegloticase maintains plasma urate at well below saturating concentrations, leading to elimination of tissue urate deposits and control of disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Davis S, Abuchowski A, Park YK, Davis FF. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol. 1981;46:649–652.
Chen RH-L, Abuchowski A, van Es T, Palczuk NC, Davis FF. Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol). Biochim Biophys Acta. 1981;660:293–298.
Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL, Abuchowski A. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316:589–596.
Davis S, Park YK, Abuchowski A, Davis FF. Hypouricaemic effect of polyethylene glycol modified urate oxidase. Lancet. 1981;2:281–283.
Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD Jr, Hershfield MS. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Int Med. 1988;109:114–1 17.
Greenberg ML, Hershfield MS. A radiochemical-high-performance liquid chromatographic assay for urate oxidase in human plasma. Anal Biochem. 1989;176:290–293.
Keilin J. The biologic significance of uric acid and guanine excretion. Biol Rev Cambridge Phil Soc. 1959;34:265–296.
Christen P, Peacock WC, Christen AE, Wacker WEC. Urate oxidase in primate phylogenesis. Eur J Biochem. 1970;12:3–5.
Wu X, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase. J Mol Evol. 1992;34:78–84.
Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002;19:640–653.
Kahn K, Serfozo P, Tipton PA. Identification of the true product of the urate oxidase reaction. J Am Chem Soc. 1997;119:5435–5442.
Kahn K, Tipton PA. Spectroscopic characterization of intermediates in the urate oxidase reaction. B. 1998;37:11651–11659.
Ramazzina I, Folli C, Secchi A, Berni R, Percudani R. Completing the uric acid degradation pathway through phylogenetic comparison of whole genomes. Nat Chem Biol. 2006;2:144–148.
Fahimi HD, Reich D, Volkl A, Baumgart E. Contributions of the immunogold technique to investigation of the biology of peroxisomes. Histochem Cell Biol. 1996;106:105–114.
Conley TG, Priest DG. Purification of uricase from mammalian tissue. Preparative Biochemistry. 1979;9:197–203.
Colloc’h N, El Haji M, Bachet B, L’Hermite G, Schiltz M, Prange T, Castro B, Mornon J-P. Crystal structure of the protein drug urate oxidase-inhibitor complex at 2.05 Å resolution. Nat Struct Biol. 1997;4:947–952.
Becker MA. Hyperuricemia and gout. In: Scriver CR, Beaudet al., Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease (ed 8th). New York: McGraw-Hill; 2001:2513–2535.
Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003;349:1647–1655.
Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206–212.
Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep. 2007;9:258–264.
Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce TE, Cairo MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia. 2003;17:499–514.
Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant. 2005;20:431–433.
Richette P, Briere C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol. 2007;34:2093–2098.
Chen RH-L, Abuchowski A, van Es T, Palczuk NC, Davis FF. Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol). Biochim Biophys Acta. 1981;660:293–298.
Savoca KV, Davis FF, Palczuk NC. Induction of tolerance in mice by uricase and monomethoxy-polyethylene glycol-modified uricase. Int Arch Allergy Appl Immunol. 1984;75:58–67.
Lee WY, Sehon AH. Suppression of reaginic antibodies with modified allergens. I. Reduction in allergenicity of protein allergens by conjugation to polyethylene glycol. Int Arch Allergy Appl Immunol. 1978;56:159–170.
Lee WY, Sehon AH, Akerblom E. Suppression of reaginic antibodies with modified allergens IV. Induction of suppressor T cells by conjugates of polyethylene glycol (PEG) and monomethoxy PEG with ovalbumin. Int Archs Allergy Appl Immun. 1981;64:100–114.
Tsuji J, Hirose K, Kasahara E, Naitoh M, Yamamoto I. Studies on the antigenicity of the polyeth ylene glycol-modified uricase. Int J Immunopharmacol. 1985;7:725–730.
Caliceti P, Schiavon O, Veronese FM. Biopharmaceutical properties of uricase conjugated to neu tral and amphiphilic polymers. Bioconjugate Chem. 1999;10:638–646.
Caliceti P, Schiavon O, Veronese FM. Immunological properties of uricase conjugated to neutral soluble polymers. Bioconjug Chem. 2001;12:515–522.
Abuchowski A, Karp D, Davis FF. Reduction of plasma urate levels in the cockerel with polyeth ylene glycol-uricase. J Pharmacol Exp Ther. 1981;219:352–354.
Hershfield MS, Chaffee S, Koro-Johnson L, Mary A, Smith AA, Short SA. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc Natl Acad Sci USA. 1991;88:7185–7189.
Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008;60:59–68.
Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery CM Jr, Jones P, Bradley A, Caskey CT. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sei USA. 1994;91:742–746.
Kelly SJ, Delnomdedieu M, Oliverio MI, Williams LD, Saifer MGP, Sherman MR, Coffman TM, Johnson GA, Hershfield MS. Diabetes insipidus in uricase-deficient mice: A model for evaluating therapy with poly(ethy lene glycol)-modified uricase. J Am Soc Nephrol. 2001;12:1001–1009.
Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006;8:R12.
Sundy JS, Ganson NJ, Kelly SJ, Scarlett E, Rehrig CD, Huang W, Hershfield MS. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56:1021–1028.
Sundy JS, Becker M, Baraf HS, Barkuizen A, Moreland LW, Huang B, Waltrip RW, Maroli AN, Horowitz Z. Reduction of plasma urate following multiple doses of pegloticase (PEG-Uricase) in subjects with treatment failure gout. Arthritis Rheum. 2008;58:2882–2891.
Sundy JS, Baraf HS, Becker M, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Yood RA, Horowitz Z, Huang B, Maroli AN, Waltrip RW. Efficacy and safety of intra venous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): Phase 3 results from GOUT1 and GOUT2. Abstract 635, American College of Rheumatology Scientific Meeting, San Francisco CA, November 2008.
Baraf HS, Becker M, Edwards NL, Gutierrez-Urena SR, Sundy JS, Treadwell EL, Vazquez-Mellado J, Yood RA, Horowitz Z, Huang B, Maroli AN, Waltrip RW. Tophus response to peglot icase (PGL) therapy: pooled results from GOUT1 and GOUT2, PGL phase 3 randomized, double blind, placebo-controlled trials. Abstract 22, American College of Rheumatology Scientific Meeting, San Francisco CA, November 2008.
Edwards NL, Baraf HS, Becker M, Gutierrez-Urena SR, Sundy JS, Treadwell EL, Vazquez-Mellado J, Yood RA, Kawata AK, Benjamin KL, Horowitz Z, Huang B, Maroli AN, Waltrip RW. Improvement in health-related quality of life (HRQL) and disability index in treatment failure gout (TFG) after peglotidase (PGL) therapy: pooled results from GOUT1 and GOUT2, phase 3 ran domized, double blind, placebo (PBO)-controlled trials. Abstract 27, American College of Rheumatology Scientific Meeting, San Francisco CA, November 2008.
Becker M, Treadwell EL, Baraf HS, Edwards NL, Gutierrez-Urena SR, Sundy JS, Vazquez-Mellado J, Yood RA, Horowitz Z, Huang B, Maroli AN, Waltrip RW, Wright D. Immunoreactivity and clinical response to pegloticase (PGL): pooled data from GOUT1 and GOUT2, PGL phase 3 randomized, double blind, placebo-controlled trials. Abstract 1945, American College of Rheumatology Scientific Meeting, San Francisco CA, November 2008.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Hershfield, M.S., Sundy, J.S., Ganson, N.J., Kelly, S.J. (2009). Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout. In: Veronese, F.M. (eds) PEGylated Protein Drugs: Basic Science and Clinical Applications. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8679-5_13
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8679-5_13
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8678-8
Online ISBN: 978-3-7643-8679-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)